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Excessive insulin signaling through the insulin receptor (IR) may play a role in the patho-
genesis of diet-induced metabolic disease, including obesity and type 2 diabetes. Here we
investigate whether heterozygous impairment of insulin receptor (IR) expression limited to
peripheral, i.e. non-CNS, tissues of adult mice impacts the development of high-fat diet-
induced metabolic deterioration. While exhibiting some features of insulin resistance, PerI-
RKO+/− mice display a hepatic energy deficit accompanied by induction of energy-sensing
AMPK, mitochondrial biogenesis, PPARα, unexpectedly leading to protection from, and
reversal of hepatic lipid accumulation (steatosis hepatis, NAFLD). Consistently, and unlike in
control mice, the PPARα activator fenofibrate fails to further affect hepatic lipid accumulation
in PerIRKO+/− mice. Taken together, and opposing previously established diabetogenic
features of insulin resistance, incomplete impairment of insulin signaling may mimic central
aspects of calorie restriction to limit hepatic lipid accumulation during conditions of metabolic
stress.
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besity is associated with increased risk of developing
various metabolic-related diseases such as type 2 diabetes,
cardiovascular disease, cancer, and non-alcoholic fatty
liver disease (NAFLD)1,2. The molecular causes of obesity-driven
metabolic disease are not fully understood but are often coupled
with the development of insulin resistance in peripheral tissue, a
pathophysiological manifestation driving metabolic disease3–5.
Insulin acts via the insulin receptor (IR)/phosphatidylinositol 3-
kinase (PI3K)/AKT2 signaling pathway to facilitate glucose
transport from the blood into skeletal muscle and adipose cells for
use in ATP production or storage as glycogen and triglycerides
(TGs), respectively. In the liver, insulin primarily acts to sup-
presses hepatic glucose production and stimulate lipogenesis and
glycogen synthesis3,6. The net effect of this coordinated response
is the lowering of blood glucose levels, and if this is not achieved
then pancreatic β-cells compensate by increasing insulin release
resulting in hyperinsulinemia, a key characteristic of insulin
resistance.
Hyperinsulinemia is fundamentally viewed as a compensatory
mechanism to correct insulin resistance. Interestingly, however,
studies that have attenuated high-calorie diet-induced hyper-
insulinemia in mice report reduced fat mass, attenuation of
NAFLD, improved insulin sensitivity, and extended lifespan7–10.
Indeed, hyperinsulinemia often precedes the development of
marked insulin resistance and fat mass gain11–13, and insulin
infusions in rodents and humans can result in insulin
resistance14,15, suggesting that excessive insulin signaling result-
ing from hyperinsulinemia may have a causative role in the
development of diet-induced obesity and associated metabolic
dysfunction. This is consistent with the hypothesis that hyper-
insulin signaling can desensitize aspects of the insulin signaling
cascade below the level of the IR16,17, and that impairment of
insulin/IGF1 signaling leads to metabolic adaptions that extend
life and health-span of Caenorhabditis elegans, Drosophila mela-
nogaster, and several mammalian models18–21.
Hepatic insulin resistance is one of the earliest pathologies to
develop in response to metabolic overload; however, it does not
affect all insulin-signaling pathways equally. Although insulin’s
ability to suppress glycogenolysis/gluconeogenesis is reduced, it
continues to promote hepatic lipogenesis22,23. This selective
insulin resistance is problematic because hyperinsulinemia will
stimulate hepatic lipid storage without lowering blood glucose
levels, contributing to the development of hepatic steatosis that
can progress to the more serious non-alcoholic steatohepatitis.
The latter reflects hepatic lipid accumulation (steatosis) combined
with overt inflammation causing hepatocyte death, fibrosis, and
impaired hepatic function2. In the current study, we questioned
whether hyperinsulinemia-driven excessive insulin signaling in
peripheral tissue contributes to the development of diet-mediated
insulin resistance, and/or NAFLD. We have previously shown
that partial peripheral tissue IR expression is sufficient for opti-
mal insulin signaling24 and therefore investigated whether redu-
cing expression of the IR in the peripheral tissue of mice fed a diet
that induces obesity could protect from metabolic dysfunction.
We report that partial disruption of the IR in peripheral tissues of
adult mice protects from high-fat diet-induced NAFLD, and
suggest that the activation of AMPK and PPARα contributes to
the altered hepatic lipid metabolism.
Results
Partial IR disruption has limited effect on body composition.
Previously we have reported that male PerIRKO+/− mice fed a
chow diet show a mild reduction in body fat mass 6 weeks fol-
lowing induction of partial IR disruption24. Here we sought to
determine whether the reduction in fat mass was increased during
conditions that promote fat mass accumulation. After 10 weeks of
HFD-feeding, male PerIRKO+/− mice had a 35–65% reduction in
IR expression in peripheral tissues such as visceral fat, liver, and
skeletal muscle (Fig. 1a and Supplementary Fig. 1a-d) compared
with HFD-fed WT mice, and HFD-induced reduction in hepatic
IR expression was similar in WT and PerIRKO+/− mice (Fig. 1e).
We have previously reported that PerIRKO+/− mice have normal
IR expression in central nervous system tissues (whole brain,
hypothalamus, and the pituitary)24. Body mass of PerIRKO+/−
mice was lower than WT, and this was attributed to a reduction
in fat mass, with no change in lean body mass (Fig. 1b–d). This
reduction was to a similar extent reported in chow-fed mice,
suggesting these mice were not further protected from HFD-
induced gains in fat mass24. The modest reduction in relative fat
mass is likely associated with a reduced food intake (Fig. 1e), as
there was no observable difference between WT and PerIRKO+/−
mice in whole-body energy expenditure, substrate utilization, or
activity levels (Fig. 1f–h). Leptin is an adipokine involved in the
regulation of energy intake, and complete peripheral IR ablation
has previously been reported to elevate plasma leptin levels and
suppress food intake25. Consistent with this, male PerIRKO+/−
mice fed a HFD had substantially elevated plasma leptin levels per
gram of fat mass (Fig. 1i), but no difference in absolute levels
(Supplementary Fig. 2d). Male mice are the focus for the
remainder of this study because female mice fed a HFD did not
gain a substantial amount of fat mass nor did they become insulin
resistant.
The effect of reduced IR expression on glucose homeostasis. As
we hypothesized that hyper-insulin signaling via the IR con-
tributes to diet-induced dysregulation of glucose homeostasis, we
next determined whether partial disruption of the IR during HFD
feeding alters glucose tolerance and insulin sensitivity. Despite
having reduced fasted blood glucose, PerIRKO+/− mice were
hyperinsulinemic in the fed state (Fig. 2a, b) and less able to
normalize blood glucose levels in response to a glucose bolus,
suggesting glucose intolerance (Fig. 2c, Supplementary Fig. 2a).
To investigate this further hyperinsulinemic–euglycemic clamps
(Fig. 2d–g) and insulin tolerance tests (ITT; Fig. 2h) were per-
formed. A lower glucose infusion rate was required to maintain
blood glucose levels of PerIRKO+/− (Fig. 2d) during clamp,
indicating these mice had impaired insulin sensitivity. This
appeared to be the result of a reduced ability for PerIRKO+/− to
suppress endogenous glucose production in response to insulin
rather than having a lower glucose clearance (Rd, Fig. 2e, f).
Consistent with hepatic receptor-mediated endocytosis having a
central role in clearing insulin26 and PerIRKO+/− having
impaired insulin sensitivity, at the end of the clamp PerIRKO+/−
plasma insulin levels were higher than that of WT mice (Fig. 2g).
Surprisingly, however the ability for PerIRKO+/− to lower blood
glucose following an injection of insulin was not impaired
(Fig. 2h, Supplementary Fig. 2b).
To assess tissue-specific insulin sensitivity the activation
(phosphorylation) of AKT was determined following an insulin
injection. Although insulin-induced AKT phosphorylation was
similar in skeletal muscle from PerIRKO+/− and WT mice
(Fig. 2i, l), white adipose tissue (WAT) basal and insulin-
stimulated AKT phosphorylation was substantially impaired in
PerIRKO+/− (Fig. 2j, m). The absolute level of hepatic AKT
phosphorylation was lower in PerIRKO+/− mice, yet insulin
treatment induced a substantial (2.9 fold) increase in AKT
phosphorylation in the livers of PerIRKO+/− but not WT mice,
suggesting an improved ability for insulin to induce hepatic AKT
activation in PerIRKO+/− (Fig. 2k, n). Consistent with overall
reduced hepatic AKT activation, basal GSK3 and FOXO1
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phosphorylation was lower in the liver of PerIRKO+/− than WT
(Supplementary Figs. 2e). While basal hepatic phosphorylation of
mTORC1 targets P70SK6 and RPS6 were not affected by partial
IR knockdown, PerIRKO+/− tended to have greater insulin-
induced RPS6 phosphorylation (Supplementary Figs. 2f).
As PerIRKO+/− mice had lower fasting blood glucose
and altered hepatic insulin signaling, we next determined
how HFD-fed PerIRKO+/− mice responded to modest
increases in blood glucose by monitoring blood glucose
levels following a meal. In contrast to the glucose tolerance
test and hyperinsulinemic–euglycemic clamp we found that
PerIRKO+/− mice were better able to lower blood glucose than
WT mice following a meal challenge (Fig. 2o), suggesting an
improved ability to lower blood glucose in response to a
physiological metabolic challenge.
As a result of enhanced insulin-induced increases in hepatic
AKT phosphorylation, we next turned our attention to the liver
and assessed hepatic energy status and gluconeogenic gene
expression. AMP-activated protein kinase (AMPK) is activated
(phosphorylated) in response to a reduction in intracellular
energy status and acts to turn off energy consuming processes,
while stimulating energy producing pathways27. PerIRKO+/−
mice had increased hepatic AMPK activation (phosphorylation)
and PGC1α expression, which likely resulted from an increase in
AMP/ATP and ADP/ATP ratio (Fig. 3a, b), indicating a hepatic
energy deficit. This was not observed under chow conditions
(Supplementary Fig. 3d). To understand what might be causing
this energy defect, we next measured the expression of glucose
regulatory genes (mRNA) in the liver. Gluconeogenic genes
Chrebp, Pepck, and G6p were not greatly altered in PerIRKO+/−
mice (Fig. 3c). In contrast, the expression of the glucose
metabolism genes glucokinase (Gk) and phosphofructokinase
(Pfkl) was attenuated in PerIRKO+/− mice, suggesting reduced
glycolysis and availability of glucose as substrate (Fig. 3c). In
agreement, PerIRKO+/− mice had reduced hepatic glycogen
(Fig. 3d) and what is likely to be a compensatory increase in gene
expression of the major hepatic glucose transporter, Glut2
(Fig. 3c). These effects were not observed under chow-fed
conditions (Supplementary Fig. 3a).
Partial IR disruption prevents and reverses fatty liver. As
















































f g h i
d e







































































































































































































Fig. 1 The effect of partial peripheral tissue IR disruption on body composition and energy expenditure in adult mice fed a high-fat diet. Ten days
following tamoxifen (TX) treatment, male mice were fed a high-fat diet (HFD) and liver insulin receptor (IR) β expression a, body mass b, body composition
c, d, food intake e, energy expenditure (EE) f, respiratory exchange ratio (RER) g and activity levels h were determined, as well as plasma leptin i. Results
are shown as means ± SE, with n’s represented as individual data point’s in figures. For body weight n= 13 for WT and 17 for PerIRKO+/−. Significance was
determined using two-tailed student’s t test. *p < 0.05, ***p < 0.001 vs WT. Gastroc: gastrocnemius muscle, TA: tibialis anterior muscle, Sub:
subcutaneous, visceral fat is the epididymal fat pad.
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Fig. 2 Partial peripheral tissue IR disruption alters glucose homeostasis in adult mice fed a high-fat diet. Ten days following tamoxifen (TX) treatment,
male mice were fed a high-fat diet (HFD) for 10 weeks and blood was collected from fed or 6 h fasted male mice and analyzed for blood glucose or plasma
insulin a, b. Glucose homeostasis and insulin sensitivity was assessed via glucose tolerance test (GTT), euglycemic–hyperinsulinemic clamp c–g, insulin
tolerance test h, and immunoblot analysis of Ser-473 phosphorylated AKT (pAKT) and total AKT and α-Tubulin (α-Tub) in gastrocnemius (Gastroc)
muscle i, l, white adipose tissue (WAT) j, m and liver k, n from WT and PerIRKO+/− mice injected (intraperitoneal) with saline or insulin (0.6 mU/g).
Blood glucose was monitoring during 6 h of fasting following a meal challenge o. Results are shown as means ± SE, with n’s represented as individual data
point’s in figures. For fast-refeed n= 13 for WT and 17 for PerIRKO+/−. Significance was determined using two-tailed student’s t test or ANOVA with LSD
post hoc analysis. *p < 0.05, **p < 0.01, vs WT, and #p < 0.05, ##p < 0.01 for within genotype effect. Rd: rate of glucose disappearance, EGP: endogenous
glucose production, AUC: area under curve.
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metabolism genes, we next assessed whether partial loss of
the peripheral tissue IR might affect hepatic lipid metabolism.
Indeed, hepatic TG accumulation was substantially reduced in
PerIRKO+/− mice independent of plasma TGs and free fatty acids
(FFA) (Fig. 4a–d). Consistent with elevated hepatic lipid turnover
and the activation of AMPK, we observed increased expression of
β-oxidation genes, reduced expression of lipogenesis genes, as well
as elevated mitochondrial citrate synthase activity in the livers of
PerIRKO+/− mice (Fig. 4e, f). This effect was not observed under
normal chow diet conditions (Supplementary Fig. 3c, and24). We
then sought to determine whether reduced hepatic steatosis in
PerIRKO+/− was associated with improved liver function. PerI-
RKO+/− showed an attenuated blood glucose response to i.p
injection of pyruvate, suggesting increased ability to suppress
hepatic gluconeogenesis, and reduced systemic markers of liver
damage (ALAT and ASAT) (Fig. 4g–i).
We next hypothesized that the energy defect in the liver of
PerIRKO+/− mice was activating AMPK, which was regulating
hepatic lipid metabolism via the transcription factors PPARα and
PGC1α. To assess the contribution of PPARα, mice were treated
with the PPARα agonist fenofibrate. Fenofibrate reduced HFD-
fed WT mice liver TG levels to a similar extent as PerIRKO+/−,
and the fenofibrate treatment of PerIRKO+/− mice did not result
in any further reduction, or alteration in fasted blood glucose
(Fig. 4j, k), potentially suggesting an overlap between these
pathways.
To determine whether targeting the IR may have potential as a
treatment for NAFLD we fed PerIRKO+/− and WT mice a HFD
for 8 week prior to the induction of partial peripheral tissue IR
disruption (Fig. 5a). Following tamoxifen treatment, PerIRKO+/−
mice had slightly lower body mass than WT, which was primarily
the result of a lower fat mass (Fig. 5a–c). Consistent with the
hypothesis that hyperinsulinemic signaling drives NAFLD
development and progression, 7 weeks following tamoxifen
treatment PerIRKO+/− had substantially lower hepatic lipid
content and plasma ALAT (Fig. 5d, e). Surprisingly, and in
contrast to when the IR was disrupted prior to HFD treatment
(Fig. 2), PerIRKO+/− showed similar glucose tolerance as WT
mice (Fig. 5f, g).
Discussion
Insulin is essential for regulating a large range of intracellular
metabolic processes; however, chronic high levels of insulin
resulting from excessive nutrient intake may also be involved in
the pathogenesis of metabolic diseases like obesity, diabetes, and
NAFLD. Here, we report that partially reducing the IR in the
peripheral tissue of adult mice fed a high-fat diet can protect
against, and reverse hepatic steatosis. In addition, we provide
evidence to suggest that reducing IR expression causes an energy
defect in the liver of HFD-fed mice, altering hepatic glucose and
hepatic lipid metabolism.
Genetic suppression of the INS1/INS28,9 or GPX17 genes in
mice has been reported to prevent diet-induced hyperinsulinemia
and protect from fatty liver disease. This is at least partially
attributed to lower insulin levels elevating energy expenditure
resulting in reduced whole-body fat mass. While we report here
that PerIRKO+/− mice had slightly lower fat mass, this was
associated with reduced food intake rather than an increase in
energy expenditure. As tamoxifen does not effectively activate the
Cre recombinase in the CNS of IR-floxed mice24,25, it would be
expected that diet-induced central hyperinsulinemic signaling
would be maintained and may explain why energy expenditure
was not altered. However, PerIRKO+/− mice had increased
plasma leptin levels relative to fat mass, which is consistent with
previous reports in mice with complete peripheral tissue25 or
adipose tissue28 IR ablation. Moreover, leptin can act in the
hypothalamus to suppress food intake29. It is unlikely that the
resulting reduction in fat mass was great enough to prevent diet-
induced hepatic lipid accumulation, suggesting an alternative
mechanism of action.
Insulin resistance is characterized by the inability for insulin to


























































































































































































Fig. 3 Partial peripheral tissue IR disruption induces an energy defect in the liver of adult mice fed a high-fat diet. Ten weeks following high-fat diet
(HFD) feeding the livers of male WT and PerIRKO+/− were collected and AMPK activation (phosphorylation), PGC1α expression a, ATP, ADP, AMP levels
b, expression of glucose metabolism genes c, and glycogen content d was determined. Results are shown as means ± SE, with n’s represented as individual
data point’s in figures. Significance was determined using two-tailed student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001 vs WT.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15623-z ARTICLE





























































































































































































































































































































































Fig. 4 The effect of partial peripheral tissue IR disruption on liver function in adult mice fed a high-fat diet. Livers from male WT and PerIRKO+/− mice
fed a high-fat diet (HFD) for 10 weeks were processed for H&E, Sirius red staining, assayed for triglyceride content a, b, and plasma triglycerides (TG) and
free fatty acids (FFA) were measured c, d. The expression of genes associated with lipid metabolism, and citrate synthase activity was determined e, f, a
pyruvate tolerance test was performed g and plasma samples were analyzed for the liver damage enzymes ALAT, ASAT h, i. Ten days following tamoxifen
(TX) treatment, male mice were fed a high-fat diet (HFD) for 10 weeks with or without the PPARα agonist fenofibrate (Fib) and liver TG j and fasted blood
glucose k was determined. Results are shown as means ± SE, with n’s represented as individual data point’s in figures. Significance was determined using
two-tailed student’s t test or ANOVA with LSD post hoc analysis; *p < 0.05 and **p < 0.01 vs WT.
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least early on in diet-induced development this resistance appears
to develop below the level of the IR16,17. In the liver, insulin
resistance selectively impairs insulin-induced suppression of
hepatic glucose production while insulin’s ability to suppress β-
oxidation and promote lipogenesis remains intact16,30. This has
led to the suggestion that the hepatic insulin-signaling cascade
branches to control hepatic glucose output and lipid metabolism,
with the mammalian target of rapamycin complex 1 (mTORC1)
signaling pathway remaining insulin-sensitive and regulating
hepatic lipogenesis31,32. As this divergence in signaling occurs
downstream of the IR, we expected that partial ablation would
suppress mTORC1 activity. However, the mTORC1 targets
P70S6K and RPS6 were not sustainably affected by partial IR
ablation, potentially suggesting that the reduction of IR is acting
primarily by altering liver glucose metabolism or through
mTORC1-independent lipogenesis regulators.
Consistent with this, the absolute levels of insulin-induced
signaling downstream of the IR (namely pAKT) were suppressed
in PerIRKO+/− mice; however, high levels of insulin (as in the
postprandial state) were still capable of activating the insulin-
signaling cascade. It is likely that this reduction in chronic
physiological signaling associated with hyperinsulinemia, as well
as altered hepatic glycogen storage and glycolysis pathway gene
expression, contribute to the observed hepatic energy depriva-
tion. Similar to physiological stressors that alter cellular energy
status, such as fasting or exercise33, PerIRKO+/− mice showed
hepatic activation of AMPK and increased expression of PPARα,
both of which are involved in lipid metabolism. Indeed, AMPK
activators can attenuate diet-induced hepatic lipid accumulation
by reducing the expression of similar hepatic lipogenesis genes
(Scd-1, Fasn) to those downregulated by partial peripheral IR
ablation34, and pharmacological activation of PPARα protects























































































































































































Fig. 5 Induction of partial peripheral tissue IR disruption following high-fat diet feeding lowers hepatic lipid content without impairing glucose
tolerance. Following 8 weeks of high-fat diet (HFD) feeding, mice were treated with tamoxifen and body mass a body composition b, c, hepatic lipid
content d and plasma ALAT e were determined, and glucose homeostasis assessed via glucose tolerance test f and blood glucose measurement g
6–7 weeks later. Results are shown as means ± SE, with n’s represented as individual data point’s in figures. For body weight and GTT n= 13 for WT and 9
for PerIRKO+/−. Significance was determined using two-tailed student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001 vs WT.
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against the development of NAFLD35,36. As treatment of PerI-
RKO+/− mice with the PPARα agonist fenofibrate did not have
an additive effect on lowering blood glucose or hepatic lipid
content, this may indicate that reduced insulin signaling protects
from hepatic steatosis by activating PPARα and AMPK signaling
to alter hepatic lipid metabolism during conditions of metabolic
overload. However, hepatic lipid storage was already sub-
stantially reduced in the livers of HFD-fed PerIRKO+/− mice,
meaning that perhaps further lowering of hepatic lipid content
with fenofibrate may not have been possible. This makes it dif-
ficult to ascertain whether partial peripheral IR ablation pro-
tection from NAFLD is entirely dependent on PPARα activation
and warrants further investigation.
An alternative hypothesis to explain hepatic selective insulin
resistance is that the liver actually remains insulin-sensitive
during nutritional overload and liver cell-non-autonomous
insulin-sensitive signaling controls hepatic glucose output.
Indeed, the Birnbaum group37–39 has provided substantial evi-
dence that insulin acts in the adipose tissue to reduce circulating
FFA, which can subsequently suppress hepatic glucose output.
Our findings may not fully support this as PerIRKO+/− had
similar FFA levels to that of WT. However, it does raise the
possibility that given the mouse model we employed has reduced
IR expression in peripheral tissues in addition to the liver38,39,
that non-hepatic cells are contributing to the protection from
NAFLD. Indeed, there is evidence of insulin signaling cross-talk
between the liver and adipose tissue with complete IR ablation
specifically in adipose tissue, leading to lipodystrophy coupled
with severe hepatic lipid accumulation and dysregulation of
gluconeogenesis40. Importantly, partial IR disruption was effec-
tive in lowering hepatic lipid storage even when induced after the
onset of metabolic dysfunction (8 weeks following of HFD
feeding), suggesting that regardless of the mechanism there is
therapeutic potential in targeting hyperinsulinemic signaling
clinically to treat NAFLD progression. Indeed, our observation
that suppressing peripheral insulin signaling does not induce
further impairments in glucose intolerance are consistent with
previous observations that reducing insulin levels in obese mice
induces fat mass loss preferentially from centrally located deposits
without effecting glucose tolerance10, and indicate that adapta-
tions associated with suppressing hyperinsulinemic signaling are
not required prior to the onset of metabolic stress to prevent
hepatic lipid accumulation.
Despite a reduced level of IR expression, insulin resistance and
fed-hyperinsulinemia, PerIRKO+/− mice had normal or reduced
fed and fasted blood glucose levels and improved ability to
shut off pyruvate-driven gluconeogenesis. This is consistent
with young or adult-induced hepatic IR KO mice being
normoglycemic32,41. However, complete IR expression appears to
be required to regulate glucose homeostasis during severe
hyperglycemia, with PerIRKO+/− mice showing pronounced
glucose intolerance when challenged with a high dose of glucose,
but not in response to a meal. Although skeletal muscle is pri-
marily responsible for insulin-induced glucose disposal, the major
defect in PerIRKO+/− insulin signaling was in WAT, suggesting
that a suppression of adipose insulin-induced glucose uptake
might be responsible for the observed glucose intolerance which
is in agreement with skeletal muscle IR KO mice showing normal
glucose homeostasis42. How this glucose intolerance was avoided
by partially disrupting the IR following the development of
obesity is not clear but suggests that targeting the IR may be more
effective treatment than preventative option for metabolic-related
pathologies.
Our findings indicate that the chronic upregulation of insulin
signaling through the peripheral IR during diet-induced obesity
contributes to the development of hepatic dysfunction, and that
targeting the IR in peripheral tissues may be an effective
approach to treat NAFLD. Future studies should address whe-
ther reducing IR expression specifically in the liver is sufficient to
mediate the observed improvements in hepatic function or
whether cross-talk between peripheral tissues is controlling
hepatic lipid accumulation.
Methods
Murine breeding and housing conditions. Mice were maintained in a
temperature-controlled facility with 12 h light–dark cycle and ad libitum access to
water and a standard chow diet (S8022-S005, ssniff diets, Soest, Germany) or a diet
with 45% of energy derived from lard (HFD, S9669-E006, ssniff diets, Soest,
Germany) with or without 0.1% fenofibrate. All experiments and blood collections
were undertaken in the dark phase. As described previously24,25, peripheral tissue
inducible IR knockout mice were generated by crossing IRlox/+ (B6.129S4(FVB)-
Insrtm1Khn/J) and CreER (B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J) mice and
backcrossing on C57Bl/6 N background resulting in IRlox/+;CreER/+, which are
referred to as PerIRKO+/−, where Per stands for peripheral. IRlox/+;+/+ littermates
were used as control (WT) mice. Cre expression was induced at 10 or 18 weeks of
age by administration of 2 mg tamoxifen (Cayman Chemicals, Michigan, USA) or
carrier via oral gavage for 5 consecutive days. WT and PerIRKO+/− received the
same dose of tamoxifen, and this resulted in the partial ablation of the IR in
peripheral, but not central tissues of PerIRKO+/− within 10 days (Supplementary
Fig. 1 and24). All experiments were approved by the Canton of Zurich Veterinary
Office, Switzerland.
Biochemical assays. Unless stated otherwise, all other reagents were purchased
from Sigma-Aldrich Chemicals (St. Louis, MO, USA). Blood glucose was deter-
mined using a handheld glucose meter (Bayer Contour XT Meter), plasma insulin
by immunoassay (Meso Scale Discovery, Gaithersburg, MD), leptin by ELISA
(Crystal Chem Inc., Chicago, Illinois, USA), and plasma FFA, TGs, ALAT, and
ASAT by enzymatic reaction (Cobas Mira; Hoffmann-La Roche, Basel, Switzer-
land). Citrate synthase activity was measured in supernatant by examining the
increase of 5,5-dithiobis-2-nitrobenzoate at a wavelength of 412 nm43. Liver TG
were extracted from liver samples as previously described7 and quantified using a
commercial enzymatic colorimetric assay (Roche Diagnostics), and glycogen was
determined by the acid-hydrolysis method44. Hematoxylin–Eosin and Sirius Red
staining was performed on paraffin sections from livers fixed in phosphate-buffered
4% formaldehyde. Images were acquired with ×10 objective on Axio Scope.A1
microscope (Oberkochen, Germany) equipped with an AxioCam MRc digital
camera (Oberkochen, Germany). Hepatic ATP and AMP levels were determined
by reverse phase high performance liquid chromatography (HPLC) as described
before45. In brief, tissue samples were removed and snap-frozen with liquid
nitrogen. Samples were homogenized in pre-chilled acetonitrile buffer to pre-
cipitate protein. Following the removal of protein for later quantification by
chloroform-extraction, the metabolite-containing fraction was subjected to HPLC
separation and detection. Metabolites were identified by spiking of samples with
appropriate standards. Metabolite content was normalized to total protein content.
Immunoblotting was performed as described previously7. In brief, tissues were
homogenized using an electrical handheld homogenizer in 10–20 volumes of ice
cold RIPA lysis buffer (50 mM HEPES (pH 7.4), 1% (vol/vol) Triton X-100, 1%
(vol/vol) sodium deoxycholate, 0.1% (vol/vol) SDS, 150 mM NaCl, 10% (vol/vol)
glycerol, 1.5 mM MgCl2, 1 mM EGTA, 50 mM sodium fluoride, protein inhibitor
cocktail (Roche, Basel, Switzerland), 1 mM phenylmethysulfonyl fluoride, 1 mM
sodium vanadate), incubated for 20 min on ice and centrifuged at 20,000 × g for
20 min at 4 °C. The supernatants were resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and processed for immunoblotting by
standard procedures. Antibody details are provided in supplementary table 1, and
uncropped western blots can be found in the Source Data File.
Metabolic and body composition measures. Insulin (ITT), glucose (GTT), and
pyruvate (PTT) tolerance tests were performed in two (ITT) or 5 h (GTT and PTT)
fasted mice by intraperitoneally injecting a bolus of insulin (0.6 mU/g; ITT), D-
glucose (2 mg/g; GTT) or sodium pyruvate (1 mg/g; PTT) and tail blood glucose
was measured at the time points indicated as described previously7. Meal challenge
experiments involved fasting mice overnight (16 h, largely during light cycle) then
allowing ad libitum access to food for 4 h before refasting and monitoring blood
glucose for the following 6 h. PhenoMaster (TSE systems, Bad Homburg, Ger-
many) open-circuit calorimetry system was used to measure oxygen consumption
and ambulatory activity over 48 h (two light–dark cycles) following a 24–48 h
acclimation period and body composition by nuclear magnetic resonance (Echo
MRI-100 Body Composition Analyzer, Echo Medical Systems, Huston, USA).
Glucose clamp studies. Glucose turnover rate was assessed in freely moving mice
after 10 weeks of HFD during an euglycemic–hyperinsulinemic clamp as previously
described46. In brief, mice were anesthetized with isoflurane, and a catheter (MRE
025, Braintree Scientific) was inserted into the right jugular vein and exteriorized at
the back of the neck. After 7 days of recovery, only mice that had regained >95% of
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their preoperative weight were studied. After a fasting period of 5 h, 3-[3 H]glucose
(0.1 μCi/min; PerkinElmer) was infused for 80 mins, and blood was collected from
tail tip for basal turnover calculation. After basal sampling, insulin (18 mU/kg/min)
was infused for 2 h. Euglycemia was maintained by periodically adjusting a variable
infusion of 20% glucose with a syringe pump (Harvard Apparatus, Holliston, MA,
USA). The glucose infusion rate was calculated as the mean of the steady-state
infusion (60–90 mins) after 1 h of insulin infusion. A blood sample was collected
from tail tip after steady-state infusion. The glucose turnover rate was calculated by
dividing the rate of 3-[3 H]glucose infusion by the plasma 3-[3 H]glucose-specific
activity. Hepatic glucose production was calculated by subtracting the glucose
infusion rate from the glucose turnover rate.
Real-time polymerase chain reaction. RNA was extracted using Trizol reagent
(Invitrogen, Carlsbad, CA), and mRNA was reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA).
Quantitative real-time PCR was performed on a ViiA 7 Real-Time PCR System
(Applied Biosystems, Foster City, CA) using the SYBR green select master mix
(Applied Biosystems, Foster City, CA) and relative quantification achieved using
the ΔΔCt method with 18 S ribosomal RNA as an internal control. Primer
sequences used are listed in Supplementary Table 2.
Statistical analyses. All data were presented as mean ± SEM. Statistical sig-
nificance was using unpaired two-tailed Student’s t test and two-way ANOVA with
fisher’s least significant difference post hoc analysis as indicated. The level of
significance was set at p < 0.05 (SPSS version 20, IBM, Armonk, NY, USA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request. A Source Data file is available for this article.
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